Tearsheet

Monte Rosa Therapeutics (GLUE)

Market Price (5/25/2026): $18.79 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Biotechnology

Monte Rosa Therapeutics (GLUE)

Market Price (5/25/2026): $18.79
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -148 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345%

Stock price has recently run up significantly
12M Rtn12 month market price return is 374%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -73%, Rev Chg QQuarterly Revenue Change % is -95%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 303%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%

Significant short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.85

Key risks
GLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33%
1	Megatrend and thematic drivers Megatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D.
2	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -148 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345%
4	Stock price has recently run up significantly 12M Rtn12 month market price return is 374%
5	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -73%, Rev Chg QQuarterly Revenue Change % is -95%
6	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45%
7	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46%
8	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 303%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%
10	Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 17.85
11	Key risks GLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more.

Valuation, Metrics & Events

	5/25/26	2025	2024	2023	2022
Share Price CYE	$18.79	$15.68	$6.94	$5.65	$7.61
Market Cap CYE ($ Bil)	1.9	1.3	0.6	0.3	0.4
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.7	0.4	0.4	0.2	0.3
Enterprise Value ($ Bil)	1.2	1.3	0.6	0.3	0.4
Valuation Ratios
P/S TTM	43.7	10.8	7.5	-	-
P/EBIT TTM	-12.7	-24.7	-7.0	-2.2	-3.3
P/E TTM	-14.4	-34.7	-7.8	-2.4	-3.4
P/FCF TTM	-95.5	-48.8	15.0	-5.1	-3.5
Sector Ratios
P/S TTM (Sector)	3.7	4.2	3.8	4.2	4.5
P/EBIT TTM (Sector)	-1.8	-1.7	-1.5	-1.5	-1.3
P/E TTM (Sector)	-2.0	-1.8	-1.7	-1.6	-1.3
P/FCF TTM (Sector)	-1.9	-1.8	-1.5	-1.4	-1.6

	5/25/26	2025	2024
Share Price CYE	$18.79	$15.68	$6.94
Market Cap CYE ($ Bil)	1.9	1.3	0.6
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.7	0.4	0.4
Enterprise Value ($ Bil)	1.2	1.3	0.6
Valuation Ratios
P/S TTM	43.7	10.8	7.5
P/EBIT TTM	-12.7	-24.7	-7.0
P/E TTM	-14.4	-34.7	-7.8
P/FCF TTM	-95.5	-48.8	15.0
Sector Ratios
P/S TTM (Sector)	3.7	4.2	3.8
P/EBIT TTM (Sector)	-1.8	-1.7	-1.5
P/E TTM (Sector)	-2.0	-1.8	-1.7
P/FCF TTM (Sector)	-1.9	-1.8	-1.5

	GLUE	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-95.0%	8.7%
Rev Chg LTM	-73.1%	7.4%
Rev Chg 3Y Avg	7,408.2%	5.8%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-345.2%	18.4%
CFO/Rev LTM	-34.2%	21.1%
Net Inc Mgn	-302.7%	13.0%
VALUATION	VERY HIGH
P/S	43.7	3.2
P/CFO	-127.9	15.2
P/FCF	-95.5	19.6
P/E	-14.4	23.9
STABILITY	VERY GOOD
Debt/Equity	0.02	0.22
Cash/Assets	0.90	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Clinical Programs	3	11062025	Link
Number of Wholly-Owned Pipeline INDs Anticipated in Next 2 Years	Multiple	11062025	Link
Potential Milestone Payments from Novartis VAV1 Collaboration	up to $2.1 billion	11062025	Link
Potential Milestone Payments from Novartis Immune-Mediated Diseases Collaboration	up to $5.7 billion	11062025	Link
Potential Milestone Payments from Roche Collaboration	>$2 billion	11062025	Link
Number of Patients to be Enrolled in MRT-2359 mCRPC Updated Clinical Results	20 to 30	11062025	Link

null

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Monte Rosa Therapeutics (GLUE) stock has lost about 10% since 1/31/2026 because of the following key factors:

1. Significant Miss in Q1 2026 Earnings and Revenue.

Monte Rosa Therapeutics reported a Q1 2026 Earnings Per Share (EPS) of -$0.45, missing analyst estimates of -$0.39 by $0.06. The company's revenue for the quarter was $4.21 million, substantially below analyst estimates of $11.1 million, leading to a net loss of $44.5 million, a sharp decline from a net income of $46.9 million in Q1 2025. This financial underperformance resulted in a 2.84% decline in the stock price the day following the earnings announcement on May 7, 2026, and a further 11.3% drift lower in the subsequent 12 days.

2. Substantial Decline in Collaboration Revenue.

A core reason for the revenue miss was a dramatic decrease in collaboration revenue, which fell to $4.2 million in Q1 2026 from $84.9 million in Q1 2025. This 95% reduction in collaboration income, coupled with a 37% year-over-year increase in Research and Development (R&D) expenses to $44.1 million, negatively impacted the company's financial performance.

Show more

Holding a concentrated position? Know your true downside before the momentum shifts.

Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -8.3% change in GLUE stock from 1/31/2026 to 5/24/2026 was primarily driven by a -76.3% change in the company's Total Revenues ($ Mil).

(LTM values as of)	1312026	5242026	Change
Stock Price ($)	20.52	18.81	-8.3%
Change Contribution By:
Total Revenues ($ Mil)	182	43	-76.3%
P/S Multiple	9.3	43.7	369.6%
Shares Outstanding (Mil)	82	100	-17.5%
Cumulative Contribution			-8.3%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/24/2026

	Return	Correlation
GLUE	-8.3%
Market (SPY)	8.1%	39.0%
Sector (XLV)	-2.7%	18.6%

Fundamental Drivers

The 46.4% change in GLUE stock from 10/31/2025 to 5/24/2026 was primarily driven by a 637.2% change in the company's P/S Multiple.

(LTM values as of)	10312025	5242026	Change
Stock Price ($)	12.85	18.81	46.4%
Change Contribution By:
Total Revenues ($ Mil)	178	43	-75.9%
P/S Multiple	5.9	43.7	637.2%
Shares Outstanding (Mil)	82	100	-17.7%
Cumulative Contribution			46.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/24/2026

	Return	Correlation
GLUE	46.4%
Market (SPY)	9.9%	19.3%
Sector (XLV)	4.8%	18.7%

Fundamental Drivers

The 283.1% change in GLUE stock from 4/30/2025 to 5/24/2026 was primarily driven by a 720.4% change in the company's P/S Multiple.

(LTM values as of)	4302025	5242026	Change
Stock Price ($)	4.91	18.81	283.1%
Change Contribution By:
Total Revenues ($ Mil)	76	43	-43.2%
P/S Multiple	5.3	43.7	720.4%
Shares Outstanding (Mil)	82	100	-17.8%
Cumulative Contribution			283.1%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/24/2026

	Return	Correlation
GLUE	283.1%
Market (SPY)	36.0%	18.5%
Sector (XLV)	8.6%	19.4%

Fundamental Drivers

The 314.3% change in GLUE stock from 4/30/2023 to 5/24/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).

(LTM values as of)	4302023	5242026	Change
Stock Price ($)	4.54	18.81	314.3%
Change Contribution By:
Total Revenues ($ Mil)	0	43	9.2233720368547763E17%
P/S Multiple	∞	43.7
Shares Outstanding (Mil)	49	100	-51.0%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/24/2026

	Return	Correlation
GLUE	314.3%
Market (SPY)	86.3%	20.2%
Sector (XLV)	18.0%	18.2%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
GLUE Return	-4%	-63%	-26%	23%	126%	20%	-11%
Peers Return	-3%	-49%	-3%	13%	2%	14%	-36%
S&P 500 Return	27%	-19%	24%	23%	16%	9%	98%
Monthly Win Rates [3]
GLUE Win Rate	71%	33%	33%	50%	50%	40%
Peers Win Rate	52%	43%	35%	48%	55%	36%
S&P 500 Win Rate	75%	42%	67%	75%	67%	60%
Max Drawdowns [4]
GLUE Max Drawdown	-	-70%	-70%	-60%	-48%	-42%
Peers Max Drawdown	-44%	-63%	-64%	-45%	-57%	-26%
S&P 500 Max Drawdown	-5%	-25%	-10%	-8%	-19%	-9%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, NRIX, ARVN, CCCC, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)

Event	GLUE	S&P 500
2025 US Tariff Shock
% Loss	-44.2%	-18.8%
% Gain to Breakeven	79.2%	23.1%
Time to Breakeven	124 days	79 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-62.7%	-9.5%
% Gain to Breakeven	168.0%	10.5%
Time to Breakeven	76 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-31.3%	-6.7%
% Gain to Breakeven	45.5%	7.1%
Time to Breakeven	34 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-69.9%	-24.5%
% Gain to Breakeven	231.9%	32.4%
Time to Breakeven	1301 days	427 days

Compare to KYMR, NRIX, ARVN, CCCC, BMY

In The Past

Monte Rosa Therapeutics's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Event	GLUE	S&P 500
2025 US Tariff Shock
% Loss	-44.2%	-18.8%
% Gain to Breakeven	79.2%	23.1%
Time to Breakeven	124 days	79 days
Summer-Fall 2023 Five Percent Yield Shock
% Loss	-62.7%	-9.5%
% Gain to Breakeven	168.0%	10.5%
Time to Breakeven	76 days	24 days
2023 SVB Regional Banking Crisis
% Loss	-31.3%	-6.7%
% Gain to Breakeven	45.5%	7.1%
Time to Breakeven	34 days	31 days
2022 Inflation Shock & Fed Tightening
% Loss	-69.9%	-24.5%
% Gain to Breakeven	231.9%	32.4%
Time to Breakeven	1301 days	427 days

Compare to KYMR, NRIX, ARVN, CCCC, BMY

In The Past

Monte Rosa Therapeutics's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Monte Rosa Therapeutics (GLUE)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

AI Analysis | Feedback

Genentech for targeted protein degradation.
Moderna for protein 'clean-up' drugs.

AI Analysis | Feedback

Oral molecular glue degrader for GSPT1: A precision medicine for the treatment of Myc-driven cancers.
CDK2: A treatment in development for ovarian, uterine, and breast cancers.
NEK7: A therapeutic target for inflammatory diseases, including Crohn's disease, neurodegenerative disease, diabetes, and liver disease.
VAV1: A target protein being developed for autoimmune diseases.
BCL11A: A therapeutically-relevant protein targeted for hemoglobinopathies.

AI Analysis | Feedback

Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biopharmaceutical company focused on the research and development of novel small molecule precision medicines. As of now, the company does not have any commercialized products on the market.

Therefore, Monte Rosa Therapeutics does not currently have major customers that purchase its products. Its primary activities are advancing its pipeline candidates through preclinical and clinical development.

AI Analysis | Feedback

null

AI Analysis | Feedback

Markus Warmuth, M.D., Chief Executive Officer

Dr. Warmuth has served as President and Chief Executive Officer of Monte Rosa Therapeutics since January 2020. He brings over 20 years of experience in drug discovery and precision medicine. Prior to Monte Rosa, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he was involved in forming new biotech companies. He also served as Chief Executive Officer of H3 Biomedicine for seven years, an oncology biopharmaceutical company, leading teams involved in developing Ceritinib and Ribociclib. Dr. Warmuth also held multiple leadership roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), contributing to the development of Ceritinib and Ribociclib, and the discovery of allosteric SHP2 and Abl inhibitors. He currently serves as a Venture Partner at Versant Ventures.

Ajim Tamboli, CFA, Chief Financial Officer

Mr. Tamboli has served as Chief Financial Officer of Monte Rosa Therapeutics since September 2020. He was instrumental in leading private and public fundraises exceeding $465 million for Monte Rosa, including an upsized $255 million IPO. Before joining Monte Rosa, Mr. Tamboli was CFO at Rodin Therapeutics, where he managed investor fundraising and supported its acquisition by Alkermes for up to $950 million. He also previously served as a founding partner of Endurant Capital Management, a healthcare-dedicated asset management firm, and worked with Columbia Management, focusing on life sciences investing and managing a global portfolio of biotech and pharmaceutical companies. Earlier in his career, he led coverage and executed IPOs and follow-on offerings for numerous biotech and healthcare companies at Lehman Brothers, Credit Suisse, and Lazard Frères.

Sharon Townson, Ph.D., Chief Scientific Officer

Dr. Townson was promoted to Chief Scientific Officer on May 30, 2024, after joining Monte Rosa as Chief Technology Officer. She brings extensive expertise in molecular glues and targeted protein degradation technology platforms. Prior to Monte Rosa, she served as Executive Director of Platform Biology at Kymera Therapeutics. Dr. Townson was also part of the leadership team at Warp Drive Bio, where she was responsible for developing a novel molecular glue approach targeting KRAS. She began her career at Pfizer as a structural biologist.

Jennifer Champoux, Chief Operating Officer

Ms. Champoux was promoted to Chief Operating Officer on May 30, 2024. She previously held the roles of Chief People and Operations Officer since March 2023 and Senior Vice President of Operations from March 2021 to March 2023 at Monte Rosa. Before joining the company, Ms. Champoux was Executive Director of Operations at H3 Biomedicine, leading operations, communications, and finance operations teams. She also led operations for the Discovery Chemistry group at Novartis Institutes for Biomedical Research in Cambridge. Her career began in various pharmaceutical development functions at Merck and Array BioPharma.

Phil Nickson, Ph.D., J.D., Chief Business and Legal Officer

Dr. Nickson was promoted to Chief Business and Legal Officer on May 30, 2024, having joined Monte Rosa in 2021 as General Counsel to support the company's IPO. In his role, he leads Monte Rosa's business development and legal departments. Prior to Monte Rosa, he spent over 10 years with Momenta Pharmaceuticals until its acquisition by Johnson and Johnson in 2020, and then supported the integration of Momenta into J&J for approximately one year.

AI Analysis | Feedback

Key Risks to Monte Rosa Therapeutics (GLUE)

Clinical Trial Success and Development Risk: As an early-stage biopharmaceutical company, Monte Rosa Therapeutics' business heavily relies on the successful development and clinical validation of its novel small molecule precision medicines. The inherent failure rates in clinical trials are high, and the success of its drug candidates, currently in Phase 1 and progressing to Phase 2, is the primary and highest-impact catalyst for the company. Biopharmaceutical drug development is a highly speculative undertaking with a substantial degree of risk.
Funding, Cash Burn, and Shareholder Dilution Risk: Developing new drugs is an expensive and capital-intensive process. Monte Rosa Therapeutics has a significant cash burn and, as an early-stage biotech, will likely require future financing, which poses a substantial risk of dilution for existing shareholders. Despite a current cash runway expected to last into 2028, recent equity raises have already highlighted concerns about potential dilution. The company has also experienced unstable profits and declining revenue forecasts.
Regulatory Approval and Unproven Technology Risk: Even with successful clinical trials, obtaining regulatory approval (e.g., from the FDA) for its drug candidates is not guaranteed and can be unpredictable, potentially hindering market entry and future opportunities. Furthermore, Monte Rosa's core molecular glue degrader technology, while innovative and promising, is still largely unproven in its broader application and commercialization, introducing an additional layer of uncertainty regarding its long-term viability and competitive standing.

AI Analysis | Feedback

null

AI Analysis | Feedback

Monte Rosa Therapeutics (symbol: GLUE) is developing precision medicines targeting various diseases. The addressable markets for their main product candidates are outlined below.

Oral molecular glue degrader for GSPT1 (Myc-driven cancers): The global Myc proto-oncogene protein market was valued at USD 1.68 billion in 2024 and is projected to grow to USD 3.06 billion by 2029. The GSPT1 segment of the global molecular glue degrader market was estimated at approximately USD 74.3 million in 2024.
CDK2 inhibitor (Ovarian, Uterine, and Breast Cancers):
- Ovarian Cancer: The global ovarian cancer treatment market size was estimated at USD 3.5 billion in 2023, with projections to reach approximately USD 6.5 billion by 2032. The global ovarian cancer drugs market size was USD 4.09 billion in 2025 and is projected to hit around USD 7.78 billion by 2035.
- Uterine Cancer: The global uterine cancer treatment market size was approximately USD 23,633.46 million (USD 23.63 billion) in 2024 and is expected to reach nearly USD 39,007.22 million (USD 39.01 billion) by 2033.
- Breast Cancer: The global breast cancer market size was estimated at USD 26.23 billion in 2025 and is predicted to increase to approximately USD 40.11 billion by 2035.
NEK7 inhibitor (Inflammatory Diseases, such as Crohn's disease, Neurodegenerative disease, Diabetes, and Liver disease):
- Crohn's Disease: The global Crohn's Disease Market was estimated at USD 11.93 billion in 2024 and is projected to grow to USD 17.83 billion by 2035.
- Neurodegenerative Disease: The global neurodegenerative disease market size is estimated to be valued at USD 55.6 billion in 2025 and is projected to reach USD 109.5 billion by 2035.
- Diabetes: The global diabetes drugs market size was valued at USD 101.48 billion in 2025 and is projected to grow to USD 283.36 billion by 2034.
- Liver Disease: A specific addressable market size for "inflammatory liver disease" was not identified in the provided search results.
VAV1 (Autoimmune Diseases): The global autoimmune disease therapeutics market is valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035.
BCL11A (Hemoglobinopathies): The global hemoglobinopathies market size is valued at USD 5.12 billion in 2025 and is predicted to increase to approximately USD 8.87 billion by 2035.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Monte Rosa Therapeutics (GLUE) over the next 2-3 years:

Milestone Payments from Novartis Collaboration for MRT-6160: Monte Rosa Therapeutics is eligible to receive significant development, regulatory, and sales milestones, potentially up to $2.1 billion, from its collaboration with Novartis for the VAV1-directed molecular glue degrader (MGD) MRT-6160. These payments are expected to begin upon the initiation of Phase 2 studies, which Novartis is anticipated to commence for MRT-6160 in immune-mediated diseases in 2026.
Advancement of MRT-2359 into Phase 2 Studies: The company plans to initiate a Phase 2 study in the third quarter of 2026 for MRT-2359, its GSPT1 degrader, in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC). This progression into a later-stage clinical trial, following encouraging Phase 1/2 data, is a key clinical catalyst that could drive future revenue.
Progression of MRT-8102 into Phase 2 Studies: Monte Rosa Therapeutics expects to share data from its GFORCE-1 study of MRT-8102, a NEK7-directed MGD for inflammatory diseases, in the second half of 2026. This is expected to lead to the initiation of the Phase 2 GFORCE-2 study in atherosclerotic cardiovascular disease (ASCVD) in 2026. Positive interim Phase 1 data showing robust activity and reduction in inflammatory markers supports this advancement.
Initiation of New Clinical Programs from the QuEEN™ Discovery Engine: Leveraging its proprietary QuEEN™ AI/ML-powered discovery engine, Monte Rosa Therapeutics anticipates submitting an Investigational New Drug (IND) application in 2026 for a CDK2 and/or cyclin E1-directed MGD. This would introduce a new oncology program into clinical development, expanding the company's pipeline and future revenue potential.

AI Analysis | Feedback

Share Issuance

Monte Rosa Therapeutics completed its Initial Public Offering (IPO) on June 24, 2021, issuing 11,700,000 shares of common stock at $19.00 per share and receiving net proceeds of $203.9 million after deducting underwriting discounts and offering costs.
The company terminated its at-the-market (ATM) equity program prospectus on January 7, 2026, after raising $24.2 million through this program.
The number of outstanding shares for Monte Rosa Therapeutics increased by 22.34% in the year prior to March 2026.

Inbound Investments

Monte Rosa Therapeutics reported collaboration revenue of $12.8 million in Q3 2025, up from $9.2 million a year prior.
The company recorded net income of $7.5 million year-to-date in Q3 2025, reflecting collaboration activity, including the completion of a $150.0 million upfront payment under a 2024 Novartis license.
In October 2023, Monte Rosa Therapeutics AG, a wholly-owned subsidiary, entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).

Capital Expenditures

Monte Rosa Therapeutics, Inc. invested $651,000 in capital expenditures in Q3 2025, a 61.6% decrease from the previous quarter.
For the last 12 months (ending around Q3 2025), capital expenditures were -$4.12 million.
The company expects its capital expenditures to continue increasing.

Interactive Breakdown

null

null

Better Bets vs. Monte Rosa Therapeutics (GLUE)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Monte Rosa (GLUE) Stock Pre-Market (+8.7%): Positive Phase 1 Data for MRT-8102	01/07/2026
2	Monte Rosa Therapeutics Earnings Notes	12/16/2025
3	Is Monte Rosa Therapeutics Stock Built to Withstand a Pullback?	10/17/2025
4	Day 6 of Gains Streak for Monte Rosa Therapeutics Stock with 51% Return (vs. 60% YTD) [10/15/2025]	10/16/2025

	Title
0	ARTICLES

Trade Ideas

Select ideas related to GLUE.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield	04302026	GEHC	GE HealthCare Technologies	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
IQV_4302026_Dip_Buyer_FCFYield	04302026	IQV	IQVIA	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
UHS_4302026_Dip_Buyer_FCFYield	04302026	UHS	Universal Health Services	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	0.0%	0.0%	0.0%
ABT_4302026_Dip_Buyer_ValueBuy	04302026	ABT	Abbott Laboratories	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.0%	0.0%	0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K	04302026	ZBIO	Zenas BioPharma	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	0.0%	0.0%	0.0%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NVTS	Navitas Semiconductor	6.5	20.0%	309.7%
RGTI	Rigetti Computing	8.7	19.9%	19.3%
HLIT	Harmonic	1.7	19.7%	53.7%
BB	BlackBerry	4.7	18.9%	108.7%
LPTH	LightPath Technologies	0.8	18.7%	56.9%
SHAZ	SharonAI	0.8	18.0%	-26.4%
AEVA	Aeva Technologies	1.5	17.8%	90.7%
DELL	Dell Technologies	194.8	16.8%	135.5%
AXTI	AXT	6.3	16.4%	761.3%
LION	Lionsgate Studios	4.3	15.8%	63.7%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
GKOS	Glaukos	6.9	-13.5%	6.5%
FBYD	Falcons Beyond Global	0.7	-13.3%	10.3%
BTGO	BitGo	0.8	-10.7%	-62.5%
IHRT	iHeartMedia	0.7	-9.6%	6.0%
HOV	Hovnanian Enterprises	0.7	-8.9%	7.9%
INBX	Inhibrx Biosciences	1.6	-8.4%	28.3%
BJ	BJ's Wholesale Club	11.3	-8.2%	-3.8%
OPTU	Optimum Communications	0.3	-7.4%	-59.9%
TE	T1 Energy	1.8	-7.3%	21.0%
ETON	Eton Pharmaceuticals	0.9	-6.9%	92.7%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
FBYD	Falcons Beyond Global	0.7	57.0%	10.3%
HIVE	HIVE Digital Technologies	1.0	51.3%	57.8%
RGTI	Rigetti Computing	8.7	48.0%	19.3%
LPTH	LightPath Technologies	0.8	47.1%	56.9%
QBTS	D-Wave Quantum	10.4	44.5%	12.4%
TE	T1 Energy	1.8	42.5%	21.0%
NVTS	Navitas Semiconductor	6.5	37.2%	309.7%
PSNL	Personalis	0.8	33.2%	6.4%
ALAB	Astera Labs	52.0	31.9%	84.5%
RXO	RXO	4.1	30.4%	92.8%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
DSGN	Design Therapeutics	0.6	-23.7%	17.0%
BTGO	BitGo	0.8	-22.0%	-62.5%
FIGR	Figure Technology Solutions	7.3	-21.6%	-16.9%
GTN-A	Gray Media	0.8	-20.4%	-29.8%
INTU	Intuit	88.9	-18.6%	-51.5%
OPTU	Optimum Communications	0.3	-17.8%	-59.9%
EIKN	Eikon Therapeutics	0.6	-17.7%	-27.3%
GKOS	Glaukos	6.9	-16.5%	6.5%
ONDS	Ondas	3.4	-14.7%	-7.2%
STRL	Sterling Infrastructure	22.5	-13.7%	139.3%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
MXL	MaxLinear	8.7	189.5%	468.9%
BAND	Bandwidth	1.9	167.5%	297.3%
WOLF	Wolfspeed	1.9	153.7%	301.4%
INOD	Innodata	3.1	119.6%	87.4%
FCEL	FuelCell Energy	1.2	105.5%	242.1%
VPG	Vishay Precision	1.5	96.9%	195.5%
PENG	Penguin Solutions	2.8	92.7%	172.0%
XMTR	Xometry	4.6	90.3%	50.0%
AXTI	AXT	6.3	87.1%	761.3%
INTC	Intel	609.1	79.5%	224.8%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
EMBC	Embecta	0.2	-63.7%	-71.6%
FWRD	Forward Air	0.3	-61.3%	-64.8%
OPTU	Optimum Communications	0.3	-60.4%	-59.9%
CABO	Cable One	0.3	-54.5%	-53.7%
PSIX	Power Solutions International	0.9	-50.3%	-32.0%
ERAS	Erasca	3.2	-50.0%	202.2%
TRDA	Entrada Therapeutics	0.3	-48.8%	-36.2%
BRBR	BellRing Brands	1.1	-45.3%	-66.7%
ULH	Universal Logistics	0.4	-42.8%	-6.0%
UI	Ubiquiti	37.0	-41.1%	10.6%

Peer Comparisons

Peers to compare with:

Financials

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Mkt Price	18.81	78.89	17.50	9.09	3.56	59.46	18.16
Mkt Cap	1.9	7.7	1.9	0.6	0.4	121.2	1.9
Rev LTM	43	51	72	89	35	48,483	62
Op Inc LTM	-148	-355	-315	-254	-103	13,591	-201
FCF LTM	-20	-244	-272	-257	-96	11,908	-170
FCF 3Y Avg	-20	-207	-186	-289	-90	12,501	-138
CFO LTM	-15	-243	-260	-254	-95	13,306	-169
CFO 3Y Avg	-13	-192	-176	-286	-89	13,780	-132

Growth & Margins

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Rev Chg LTM	-73.1%	-12.6%	27.2%	-79.1%	-12.4%	1.8%	-12.5%
Rev Chg 3Y Avg	-	10.6%	30.3%	123.9%	19.9%	1.9%	19.9%
Rev Chg Q	-95.0%	55.5%	-66.1%	-91.7%	-15.0%	2.6%	-40.6%
QoQ Delta Rev Chg LTM	-65.3%	31.3%	-14.5%	-66.0%	-3.0%	0.6%	-8.8%
Op Inc Chg LTM	-6,864.7%	-27.7%	-36.7%	-165.4%	11.5%	72.7%	-32.2%
Op Inc Chg 3Y Avg	-2,261.3%	-30.2%	-22.9%	-41.6%	8.3%	21.0%	-26.5%
Op Mgn LTM	-345.2%	-690.2%	-439.3%	-283.8%	-295.8%	28.0%	-320.5%
Op Mgn 3Y Avg	-4,626.7%	-460.2%	-347.5%	-287.7%	-416.8%	20.2%	-382.2%
QoQ Delta Op Mgn LTM	-301.4%	191.1%	-99.1%	-238.7%	-5.1%	-0.4%	-52.1%
CFO/Rev LTM	-34.2%	-471.3%	-362.6%	-284.2%	-273.5%	27.4%	-278.9%
CFO/Rev 3Y Avg	-1,838.8%	-330.9%	-265.0%	-279.9%	-311.3%	29.2%	-295.6%
FCF/Rev LTM	-45.8%	-474.0%	-378.7%	-287.4%	-274.9%	24.6%	-281.1%
FCF/Rev 3Y Avg	-2,195.8%	-351.2%	-279.9%	-282.0%	-313.6%	26.5%	-297.8%

Valuation

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
Mkt Cap	1.9	7.7	1.9	0.6	0.4	121.2	1.9
P/S	43.7	149.5	26.8	6.5	12.9	2.5	19.9
P/Op Inc	-12.7	-21.7	-6.1	-2.3	-4.4	8.9	-5.2
P/EBIT	-12.7	-24.5	-6.1	-2.3	-4.4	10.6	-5.2
P/E	-14.5	-24.4	-6.5	-2.6	-4.3	16.7	-5.4
P/CFO	-128.0	-31.7	-7.4	-2.3	-4.7	9.1	-6.1
Total Yield	-6.9%	-4.1%	-15.3%	-38.0%	-23.1%	10.2%	-11.1%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	4.2%	0.0%
FCF Yield 3Y Avg	-3.2%	-6.2%	-15.5%	-33.2%	-38.8%	10.5%	-10.9%
D/E	0.0	0.0	0.0	0.0	0.1	0.4	0.0
Net D/E	-0.3	-0.1	-0.3	-1.0	-0.4	0.3	-0.3

Returns

	GLUE	KYMR	NRIX	ARVN	CCCC	BMY	Median
Name	Monte Ro.	Kymera T.	Nurix Th.	Arvinas	C4 Thera.	Bristol-.
1M Rtn	-5.0%	-7.1%	4.9%	-12.9%	23.6%	1.3%	-1.8%
3M Rtn	-0.9%	-9.7%	10.9%	-24.2%	64.8%	-1.0%	-0.9%
6M Rtn	32.3%	19.5%	4.4%	-21.1%	45.9%	31.4%	25.4%
12M Rtn	373.8%	167.5%	80.0%	39.6%	158.0%	33.3%	119.0%
3Y Rtn	207.4%	172.4%	79.9%	-60.1%	14.7%	5.8%	47.3%
1M Excs Rtn	-11.9%	-14.6%	0.5%	-17.9%	14.7%	-4.4%	-8.1%
3M Excs Rtn	-12.9%	-20.1%	4.5%	-35.4%	45.5%	-11.2%	-12.1%
6M Excs Rtn	20.5%	9.2%	9.6%	-33.7%	29.9%	20.2%	14.9%
12M Excs Rtn	341.2%	134.0%	51.1%	17.6%	133.9%	5.0%	92.5%
3Y Excs Rtn	153.2%	85.6%	-4.9%	-140.5%	-66.3%	-77.0%	-35.6%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	3/31/2026	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	5/7/2026	3/17/2026	3/20/2025	3/14/2024	3/16/2023	3/29/2022	6/21/2021
Key Financials
Total Revenue	43	124	76	0	0	0	0
EBITDA	-140	-46	-73	-137	-109	-71	-27
Operating Income	-148	-54	-81	-143	-112	-73	-28
Net Income	-130	-39	-73	-135	-109	-74	-36
EPS	-1.63	-0.46	-0.98	-2.63	-2.30	-2.96	-1.65
Growth Rates
Total Revenue Growth	-73.1%	63.5%	∞%	-	-	-	-
EBITDA Growth	-2378.1%	37.2%	46.8%	-26.2%	-53.6%	-157.5%	-258.3%
Operating Income Growth	-6864.7%	33.2%	43.4%	-27.5%	-54.2%	-160.2%	-250.4%
Net Income Growth	-2213.0%	46.9%	46.3%	-24.7%	-46.7%	-106.1%	-363.6%
Margins
EBITDA Margin	-325.8%	-37.1%	-96.5%	-	-	-	-
Operating Income Margin	-345.2%	-43.8%	-107.3%	-	-	-	-
Net Income Margin	-302.7%	-31.2%	-96.1%	-	-	-	-
Cash & Debt
Total Cash	666	377	372	232	263	346	42
Total Debt	39	39	43	46	47	0	0
Net Debt / (Cash)	-627	-338	-329	-186	-216	-346	-42
Cash Flows
Net Cash from Operations	-15	-23	42	-44	-92	-59	-23
Free Cash from Operations	-20	-27	38	-63	-105	-69	-26
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	0	0	1	0	-0	-0	-0

$ Mil \| FY: 12/31	2026Q1	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2
Period End	3/31/2026	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023
Filing Date	5/7/2026	3/17/2026	11/6/2025	8/7/2025	5/8/2025	3/20/2025	11/7/2024	8/8/2024	5/9/2024	3/14/2024	11/9/2023	8/10/2023
Key Financials Quarterly
Total Revenue	4	3	13	23	85	61	9	5	1	0	0	0
Ebitda	-48	-48	-31	-13	46	15	-24	-31	-33	-33	-35	-36
Operating Income	-50	-50	-33	-16	44	13	-27	-33	-35	-35	-37	-37
Net Income	-45	-46	-27	-12	47	13	-24	-30	-32	-33	-35	-35
EPS	-0.45	-0.70	-0.33	-0.15	0.57	0.22	-0.29	-0.43	-0.53	-0.58	-0.70	-0.71
Key Financials TTM
Total Revenue TTM	43	124	182	178	159	76	15	6	1	0	0	0
Ebitda TTM	-140	-46	17	23	6	-73	-121	-132	-137	-137	-135	-128
Operating Income TTM	-148	-54	9	15	-2	-81	-129	-139	-144	-143	-141	-132
Net Income TTM	-130	-39	21	24	6	-73	-119	-130	-135	-135	-133	-125
Growth Rates Quarterly
Total Revenue Growth	-95.0%	-95.4%	38.5%	394.0%	7882.0%	-	-	-	-	-	-	-
EBITDA Growth	-204.2%	-416.1%	-26.4%	56.1%	239.4%	145.6%	30.5%	14.6%	0.2%	-5.1%	-28.6%	-36.0%
Operating Income Growth	-213.6%	-482.3%	-24.3%	52.3%	226.0%	137.3%	28.2%	12.3%	-2.0%	-7.3%	-30.3%	-36.7%
Net Income Growth	-194.9%	-443.3%	-13.5%	59.4%	246.7%	140.4%	31.6%	13.8%	0.2%	-8.0%	-27.7%	-32.9%
Margins Quarterly
EBITDA Margin	-1140.3%	-1712.6%	-241.9%	-57.9%	54.3%	24.8%	-265.0%	-651.4%	-3106.2%	-	-	-
Operating Income Margin	-1188.5%	-1787.7%	-258.3%	-67.1%	51.9%	21.4%	-287.8%	-695.3%	-3284.5%	-	-	-
Net Income Margin	-1057.1%	-1658.9%	-212.1%	-53.0%	55.2%	22.2%	-258.9%	-645.6%	-3004.5%	-	-	-
Cash & Debt
Total Cash	666	377	391	291	326	372	242	262	193	232	178	203
Total Debt	39	39	40	41	42	43	44	44	45	46	46	47
Net Debt / (Cash)	-627	-338	-351	-249	-284	-329	-198	-218	-148	-186	-132	-156
Cash Flows Quarterly
FCF from Operations	-37	-43	100	-35	-45	129	-21	-28	-38	30	-25	-25
Cash Flows TTM
FCF from Operations TTM	-15	-23	149	28	35	42	-57	-61	-59	-44	-97	-93
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	0	-0	-0	-0	-0	-0	-0	-0	0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-48.1%	-53.4%	-36.2%	-14.7%	45.2%	13.5%	-23.1%	-30.0%	-34.7%	-38.8%	-38.4%	-41.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-35.1%	-14.2%	2.5%	3.0%	-0.4%	-24.4%	-28.1%	-32.1%	-35.8%	-39.9%	-36.6%	-37.2%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)	76	0
Total	76	0

Operating Income by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)		-143
Total		-143

Net Income by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)	-73	-135
Total	-73	-135

Assets by Segment

$ Mil	2025	2024	2023	2022
Developing a portfolio of novel and proprietary molecular glue degraders (MGDs)			342	366
Total			342	366

Price Behavior

Price Behavior

Market Price	$18.81
Market Cap ($ Bil)	1.6
First Trading Date	06/24/2021
Distance from 52W High	-25.7%
	50 Days	200 Days
DMA Price	$17.99	$14.63
DMA Trend	up	up
Distance from DMA	4.6%	28.6%
	3M	1YR
Volatility	50.7%	93.1%
Downside Capture	195.99	83.96
Upside Capture	134.86	242.37
Correlation (SPY)	36.9%	17.2%

GLUE Betas & Captures as of 4/30/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.16	1.38	1.24	1.16	1.34	1.42
Up Beta	1.09	0.71	1.00	2.20	2.03	1.29
Down Beta	-12.06	0.81	0.73	1.37	-0.32	0.92
Up Capture	180%	196%	121%	141%	440%	1019%
Bmk +ve Days	15	22	31	66	141	428
Stock +ve Days	12	18	27	58	124	365
Down Capture	128%	170%	166%	35%	95%	110%
Bmk -ve Days	4	18	30	56	108	321
Stock -ve Days	9	24	36	66	125	376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	349.1%	92.7%	2.00	-
Sector ETF (XLV)	16.0%	14.5%	0.80	15.3%
Equity (SPY)	29.5%	12.0%	1.86	17.1%
Gold (GLD)	35.5%	26.8%	1.11	8.0%
Commodities (DBC)	42.9%	18.7%	1.77	-6.4%
Real Estate (VNQ)	15.2%	13.1%	0.82	5.8%
Bitcoin (BTCUSD)	-31.3%	41.8%	-0.78	7.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	-3.3%	101.6%	0.40	-
Sector ETF (XLV)	5.7%	14.7%	0.21	23.9%
Equity (SPY)	14.0%	17.0%	0.64	27.5%
Gold (GLD)	18.8%	18.0%	0.85	4.5%
Commodities (DBC)	10.4%	19.4%	0.42	-1.9%
Real Estate (VNQ)	3.8%	18.8%	0.10	23.6%
Bitcoin (BTCUSD)	11.6%	55.3%	0.41	17.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with GLUE
GLUE	-1.7%	101.6%	0.40	-
Sector ETF (XLV)	9.9%	16.5%	0.49	23.9%
Equity (SPY)	15.7%	17.9%	0.75	27.5%
Gold (GLD)	13.0%	16.0%	0.67	4.5%
Commodities (DBC)	7.8%	17.9%	0.35	-1.9%
Real Estate (VNQ)	5.5%	20.7%	0.23	23.6%
Bitcoin (BTCUSD)	66.7%	66.9%	1.06	17.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	4302026
Short Interest: Shares Quantity	15.1 Mil
Short Interest: % Change Since 4152026	-4.4%
Average Daily Volume	0.8 Mil
Days-to-Cover Short Interest	17.8 days
Basic Shares Quantity	99.9 Mil
Short % of Basic Shares	15.2%

Returns Analyses

	Title
0	Is Monte Rosa Therapeutics Stock Built to Withstand a Pullback?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
3/17/2026	-2.0%	-8.1%	11.5%
11/6/2025	5.7%	15.0%	45.0%
8/7/2025	-2.9%	2.0%	13.4%
3/20/2025	5.4%	-18.1%	-32.1%
11/7/2024	0.8%	-8.7%	-0.4%
5/9/2024	-1.5%	-0.6%	-24.3%
11/9/2023	-10.6%	-0.3%	17.3%
8/10/2023	-1.6%	-4.7%	-12.1%
...
SUMMARY STATS
# Positive	8	7	9
# Negative	6	7	5
Median Positive	5.3%	7.2%	11.5%
Median Negative	-2.4%	-8.1%	-24.3%
Max Positive	16.3%	37.5%	45.0%
Max Negative	-10.6%	-18.1%	-32.1%

	Forward Returns
3/17/2026	-2.0%	-8.1%	11.5%
11/6/2025	5.7%	15.0%	45.0%
8/7/2025	-2.9%	2.0%	13.4%
3/20/2025	5.4%	-18.1%	-32.1%
11/7/2024	0.8%	-8.7%	-0.4%
5/9/2024	-1.5%	-0.6%	-24.3%
11/9/2023	-10.6%	-0.3%	17.3%
8/10/2023	-1.6%	-4.7%	-12.1%
3/16/2023	7.4%	7.2%	4.9%
11/10/2022	5.3%	21.8%	12.9%
8/11/2022	5.2%	3.6%	4.0%
3/29/2022	16.3%	37.5%	7.0%
11/12/2021	2.3%	-13.8%	-28.3%
8/12/2021	-3.9%	0.4%	4.1%
SUMMARY STATS
# Positive	8	7	9
# Negative	6	7	5
Median Positive	5.3%	7.2%	11.5%
Median Negative	-2.4%	-8.1%	-24.3%
Max Positive	16.3%	37.5%	45.0%
Max Negative	-10.6%	-18.1%	-32.1%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
03/31/2026	05/07/2026	10-Q
12/31/2025	03/17/2026	10-K
09/30/2025	11/06/2025	10-Q
06/30/2025	08/07/2025	10-Q
03/31/2025	05/08/2025	10-Q
12/31/2024	03/20/2025	10-K
09/30/2024	11/07/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/09/2024	10-Q
12/31/2023	03/14/2024	10-K
09/30/2023	11/09/2023	10-Q
06/30/2023	08/10/2023	10-Q
03/31/2023	05/11/2023	10-Q
12/31/2022	03/16/2023	10-K
09/30/2022	11/10/2022	10-Q
06/30/2022	08/11/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q1 2026 Earnings Reported 5/7/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2029 Cash Runway

Prior: Q4 2025 Earnings Reported 3/17/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2029 Cash Runway						Raised	Guidance: 2,028 for 2028

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Manning, Anthony M		Direct	Sell	5222026	18.01	10,000			Form
2	Warmuth, Markus	President & CEO	Direct	Sell	5052026	18.92	5,467	103,447	11,353,276	Form
3	Warmuth, Markus	President & CEO	Direct	Sell	4152026	17.64	8,000	141,125	10,680,872	Form
4	Nickson, Philip	Chief Business & Legal Officer	Direct	Sell	4102026	17.69	5,845	103,413	973,088	Form
5	Warmuth, Markus	President & CEO	Direct	Sell	3042026	17.92	5,466	97,974	10,996,038	Form

GLUE Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

Looking for high-conviction positions with a better risk/reward profile? See what's currently in the Trefis High Quality Portfolio.

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing GLUE?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What GLUE Makes & Who Pays

TTM figures based on

GLUE Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Monte Rosa Therapeutics (GLUE)

Market Price (5/25/2026): $18.79 | Market Cap: $1.9 BilSector: Health Care | Industry: Biotechnology

Monte Rosa Therapeutics (GLUE)

Market Price (5/25/2026): $18.79Market Cap: $1.9 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

In The Past

Preserve Wealth

Asset Allocation

About Monte Rosa Therapeutics (GLUE)

Key Risks to Monte Rosa Therapeutics (GLUE)

Interactive Breakdown

Better Bets vs. Monte Rosa Therapeutics (GLUE)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

GLUE Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

null

Market Price (5/25/2026): $18.79 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (5/25/2026): $18.79
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Biotechnology